Drug intelligence / Profile preview

Neotrofin C F

Development stage: Unknown
Lead developer: BioCen
Modality: Small Molecules
Administration: Oral

Overview

**Neotrofin C F** is an oral nutritional hematinic supplement developed and manufactured by BioCen in Cuba. It is a fixed-dose tablet containing heme iron, vitamin C, and folic acid; published BioCen-associated literature describes its antianemic product line as using enzymatic bovine-blood hydrolysate as a source of heme iron. The product is used primarily to prevent anemia, particularly during pregnancy, while vitamin C supports intestinal iron absorption and folic acid supplementation supports prevention of neural tube defects.

Brand names: Neotrofin C F
Other names: Neotrofin CF

Beyond the preview

Go deeper on Neotrofin C F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neotrofin C F.

Explore the full profile